Page 30«..1020..29303132..4050..»

VOR BIOPHARMA INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) – Marketscreener.com

By daniellenierenberg

VOR BIOPHARMA INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)  Marketscreener.com

Read the rest here:
VOR BIOPHARMA INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) - Marketscreener.com

To Read More: VOR BIOPHARMA INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) – Marketscreener.com
categoriaBone Marrow Stem Cells commentoComments Off on VOR BIOPHARMA INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) – Marketscreener.com | dataMarch 25th, 2023
Read All

MAGENTA THERAPEUTICS, INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) – Marketscreener.com

By daniellenierenberg

MAGENTA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)  Marketscreener.com

Read the original post:
MAGENTA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com

To Read More: MAGENTA THERAPEUTICS, INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) – Marketscreener.com
categoriaCardiac Stem Cells commentoComments Off on MAGENTA THERAPEUTICS, INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) – Marketscreener.com | dataMarch 25th, 2023
Read All

BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100 – Marketscreener.com

By daniellenierenberg

BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100  Marketscreener.com

Read more:
BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100 - Marketscreener.com

To Read More: BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100 – Marketscreener.com
categoriaBone Marrow Stem Cells commentoComments Off on BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100 – Marketscreener.com | dataMarch 17th, 2023
Read All

BioSenic delivers a new post-hoc analysis of its Phase III JTA-004 trial on knee osteo-arthritis with positive action on the most severely affected…

By daniellenierenberg

BioSenic delivers a new post-hoc analysis of its Phase III JTA-004 trial on knee osteo-arthritis with positive action on the most severely affected patient population  Marketscreener.com

Visit link:
BioSenic delivers a new post-hoc analysis of its Phase III JTA-004 trial on knee osteo-arthritis with positive action on the most severely affected...

To Read More: BioSenic delivers a new post-hoc analysis of its Phase III JTA-004 trial on knee osteo-arthritis with positive action on the most severely affected…
categoriaBone Marrow Stem Cells commentoComments Off on BioSenic delivers a new post-hoc analysis of its Phase III JTA-004 trial on knee osteo-arthritis with positive action on the most severely affected… | dataMarch 17th, 2023
Read All

Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in – EIN News

By daniellenierenberg

Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in  EIN News

Read the original post:
Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in - EIN News

To Read More: Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in – EIN News
categoriaSpinal Cord Stem Cells commentoComments Off on Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in – EIN News | dataMarch 17th, 2023
Read All

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate Update

By Dr. Matthew Watson

Company to host conference call March 16, 2023, at 4:30 PM EDT Company to host conference call March 16, 2023, at 4:30 PM EDT

More here:
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate Update

To Read More: Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate Update
categoriaGlobal News Feed commentoComments Off on Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate Update | dataMarch 17th, 2023
Read All

Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

By Dr. Matthew Watson

Announced SC291 IND clearance with goal to report initial clinical data this year

Originally posted here:
Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

To Read More: Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
categoriaGlobal News Feed commentoComments Off on Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates | dataMarch 17th, 2023
Read All

Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates

By Dr. Matthew Watson

Management to host conference call on Wednesday, March 22 at 4:30 p.m. ET Management to host conference call on Wednesday, March 22 at 4:30 p.m. ET

See more here:
Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates

To Read More: Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
categoriaGlobal News Feed commentoComments Off on Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates | dataMarch 17th, 2023
Read All

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates

By Dr. Matthew Watson

Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer

Read more:
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates

To Read More: ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates
categoriaGlobal News Feed commentoComments Off on ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates | dataMarch 17th, 2023
Read All

Tonix Pharmaceuticals Announces Presentation at the Rare Disease Innovation and Partnership Summit

By Dr. Matthew Watson

CHATHAM, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Herbert Harris, M.D., Ph.D., Executive Vice President, Translational Medicine of Tonix Pharmaceuticals, will deliver a presentation at the Rare Disease Innovation and Partnership Summit, which will be held as a hybrid event in Philadelphia, Pa., March 21 - March 23, 2023. A copy of the Company’s presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional information can be found on the Rare Disease Innovation and Partnership Summit website here.

Read the original:
Tonix Pharmaceuticals Announces Presentation at the Rare Disease Innovation and Partnership Summit

To Read More: Tonix Pharmaceuticals Announces Presentation at the Rare Disease Innovation and Partnership Summit
categoriaGlobal News Feed commentoComments Off on Tonix Pharmaceuticals Announces Presentation at the Rare Disease Innovation and Partnership Summit | dataMarch 17th, 2023
Read All

MedAvail to Report Fourth Quarter and Full Year 2022 Financial Results on March 30

By Dr. Matthew Watson

Management to host investor conference call and webcast at 4:30pm ET on that day Management to host investor conference call and webcast at 4:30pm ET on that day

Read more here:
MedAvail to Report Fourth Quarter and Full Year 2022 Financial Results on March 30

To Read More: MedAvail to Report Fourth Quarter and Full Year 2022 Financial Results on March 30
categoriaGlobal News Feed commentoComments Off on MedAvail to Report Fourth Quarter and Full Year 2022 Financial Results on March 30 | dataMarch 17th, 2023
Read All

Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all…

By Dr. Matthew Watson

See the original post:
Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all...

To Read More: Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all…
categoriaGlobal News Feed commentoComments Off on Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all… | dataMarch 17th, 2023
Read All

Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug Development

By Dr. Matthew Watson

EDISON, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic diseases, announces that its Chief Executive Officer, Robert Foster, PharmD, PhD, and its Senior Vice President for Clinical Pharmacology and Analytics, Patrick Mayo, PhD, will be presenting during a webinar entitled “How Artificial Intelligence is Changing Drug Discovery” on Thursday, March 23rd at 1:00 p.m. Eastern Time.

More here:
Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug Development

To Read More: Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug Development
categoriaGlobal News Feed commentoComments Off on Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug Development | dataMarch 17th, 2023
Read All

Panbela Provides Business Update and Reports Q4 and FY 2022 Financial Results

By Dr. Matthew Watson

MINNEAPOLIS, March 16, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter and full year ended December 31, 2022. As previously announced, management is hosting earnings call today at 4:30 p.m. ET.

Continued here:
Panbela Provides Business Update and Reports Q4 and FY 2022 Financial Results

To Read More: Panbela Provides Business Update and Reports Q4 and FY 2022 Financial Results
categoriaGlobal News Feed commentoComments Off on Panbela Provides Business Update and Reports Q4 and FY 2022 Financial Results | dataMarch 17th, 2023
Read All

SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update

By Dr. Matthew Watson

Phase 3 REGAL GPS AML Study on Track for Interim Analysis by Late 2023/Early 2024

View original post here:
SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update

To Read More: SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update
categoriaGlobal News Feed commentoComments Off on SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update | dataMarch 17th, 2023
Read All

Tilray Brands Stockholders Approve Charter Amendment to Enhance Corporate Governance and Support Strategic Growth Plan

By Dr. Matthew Watson

NEW YORK and LEAMINGTON, Ontario, March 16, 2023 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray Brands” or the “Company”) (NASDAQ | TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, announced today that Tilray Brands’ stockholders formally approved an amendment to the Company’s Certificate of Incorporation (the “Charter Amendment”). The Charter Amendment will, at the effective time of filing, cancel the Company’s authorized but unissued Class 1 Common Stock and re-allocate such authorized shares to Class 2 Common Stock. At the effective time of filing the Charter Amendment, the Company’s “Class 2 Common Stock” will be reclassified and designated as “Common Stock”. The Charter Amendment is described in more detail in the Company’s Proxy Statement dated September 22, 2022, as supplemented on February 21, 2023.

Go here to read the rest:
Tilray Brands Stockholders Approve Charter Amendment to Enhance Corporate Governance and Support Strategic Growth Plan

To Read More: Tilray Brands Stockholders Approve Charter Amendment to Enhance Corporate Governance and Support Strategic Growth Plan
categoriaGlobal News Feed commentoComments Off on Tilray Brands Stockholders Approve Charter Amendment to Enhance Corporate Governance and Support Strategic Growth Plan | dataMarch 17th, 2023
Read All

Lifecore Biomedical Reports Second Quarter Fiscal Year 2023 Results

By Dr. Matthew Watson

Company Announces Intention to Explore Strategic AlternativesSigns Term Sheet with Key Customer to Materially Expand Commercial RelationshipExpands Development Pipeline from 24 to 25 Active Projects as of Fiscal Second Quarter-endSubsequently Transitioned Three Projects to Commercialization with FDA Approval in Fiscal Third Quarter, Expanding Commercial Products from 26 to 29 with 14 CustomersFiscal Second Quarter Earnings Call Scheduled for March 17th, 2023 at 8:30 am Eastern Time

Read more from the original source:
Lifecore Biomedical Reports Second Quarter Fiscal Year 2023 Results

To Read More: Lifecore Biomedical Reports Second Quarter Fiscal Year 2023 Results
categoriaGlobal News Feed commentoComments Off on Lifecore Biomedical Reports Second Quarter Fiscal Year 2023 Results | dataMarch 17th, 2023
Read All

Lifecore Biomedical Announces Intent to Explore Strategic Alternatives

By Dr. Matthew Watson

CHASKA, Minn., March 16, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the Board of Directors of the Company (the “Board”) intends to initiate a process to evaluate the Company’s potential strategic alternatives to maximize value for stockholders. As part of the process, the Board intends to consider a full range of strategic alternatives, which could include a sale of the Company, potential debt or equity financing transactions, or other possible strategic transactions.

Excerpt from:
Lifecore Biomedical Announces Intent to Explore Strategic Alternatives

To Read More: Lifecore Biomedical Announces Intent to Explore Strategic Alternatives
categoriaGlobal News Feed commentoComments Off on Lifecore Biomedical Announces Intent to Explore Strategic Alternatives | dataMarch 17th, 2023
Read All

Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update

By Dr. Matthew Watson

Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET

Go here to see the original:
Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update

To Read More: Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update
categoriaGlobal News Feed commentoComments Off on Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update | dataMarch 17th, 2023
Read All

Lifecore Biomedical Signs Term Sheet with Existing Long-Term Customer to Expand CDMO Relationship

By Dr. Matthew Watson

Provides $10 million upfront cash commitment to Lifecore for infrastructure preparation and production capacity preparation

Visit link:
Lifecore Biomedical Signs Term Sheet with Existing Long-Term Customer to Expand CDMO Relationship

To Read More: Lifecore Biomedical Signs Term Sheet with Existing Long-Term Customer to Expand CDMO Relationship
categoriaGlobal News Feed commentoComments Off on Lifecore Biomedical Signs Term Sheet with Existing Long-Term Customer to Expand CDMO Relationship | dataMarch 17th, 2023
Read All

Page 30«..1020..29303132..4050..»


Copyright :: 2024